Clinical Trial Update: Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant study of ACE (doxorubicin/cyclophosphamide followed by eribulin) for operable HER2-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Eribulin (eribulin mesilate)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN